Atlas market file · Equity · United States
Nrc HealthNRC
- Last close
- 20.34
- Change
- +4.47%
- 96-bar range
- 14.71 – 23.68
- As of
- 7 Aug 2026
Nrc Health is a services-commercial physical & biological research issuer listed as NRC on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-7.04% over the window).
Source rail: Yahoo Finance chart API (NRC). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for NRC. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
NRC public profile
Services-commercial physical & biological research issuer. Nrc Health is connected to current market context, cited company sources and its retained research file.
Nrc Health trades as NRC on NASDAQ. Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files NRC under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Nrc Health today
NRC Health, the Nebraska-based healthcare-experience outfit, reported quarterly revenue of $34.8 million for the three months ending 31 March 2026, up from $33.6 million a year earlier, driven mainly by subscription-based services that let hospitals and clinics outsource the emotional labour of patient feedback to a dashboard. Operating income clocked in at $5.6 million, while operating cash flow was a healthier $7.2 million, giving the business enough oxygen to keep the lights on and the software licences renewed. The filings, however, read less like a growth story and more like a cash-flow tale, with the balance sheet sporting $121.1 million of liabilities against just $13.5 million of shareholders’ equity and a cash pile of $2.5 million that would struggle to cover a single quarter’s payroll if the subscription renewals stumbled. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/70487/000143774926015083/nrc20260331_10q.htm)
What NRC actually sells is a bundle of patient-experience software and advisory services marketed as a way to turn raw survey data into “clear action” for hospital boards that would rather not read 12,000 verbatim comments before lunch. The patient-experience platform promises lasting patient-provider relationships, while the advisory page promises expert advisors who will transform data into decisions. The gap between the marketing copy and the 10-Q’s admission that direct expenses rose to $13.6 million-mostly third-party software subscriptions and IT contractors-suggests the relationships may be built on rented code and gig labour rather than bespoke care. The company’s imagery leans hard on awards like “Best in KLAS,” but the only award the cash register recognises is the one that keeps the servers breathing. (source: NRC product pages, https://www.nrchealth.com/solutions/patient-experience/ and https://nrchealth.com/advisory-services/)
The company’s latest SEC submissions show a busy filing trail stack: an April 2026 8-K announcing amendments to equity awards for unnamed executives, followed by a flurry of Form 4s on 25 June 2026 that disclose director trades within the same week the board approved changes to prior awards. The filings do not say whether the award tweaks were repricings, retention sweeteners, or just the corporate version of a loyalty-card upgrade, but the timing is neat: when the cash balance is $2.5 million and the liabilities are north of $120 million, even a small adjustment to dilution can feel like a big story. The company’s weighted-average diluted share count sits at 21.9 million, and with EPS of $0.14 for the quarter, the arithmetic is plain: spread the $7.2 million operating cash flow across 21.9 million shares and you’re left wondering which line item is really doing the heavy lifting. (source: SEC EDGAR 10-Q, 8-K and Form 4s, https://www.sec.gov/Archives/edgar/data/70487/000143774926015083/nrc20260331_10q.htm)
For readers who like to chase charts, the SEC filings do not supply a pricing ticker or a TradingView route, so the only way to plot the stock’s mood is through the company’s own liquidity numbers and the board’s equity machinations. The cash balance of $2.5 million and the $1.8 million spent on property, plant, and equipment in the quarter suggest a company that is still investing in its own infrastructure while hoping the subscriptions keep rolling in. Meanwhile, the absence of any dividend or buyback language in the filings keeps the shareholder-return narrative on ice. If the next catalyst is a new product release or a customer win, the evidence so far offers no named press release or SEC filing to anchor it. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/70487/000143774926015083/nrc20260331_10q.htm)
The company’s own product pages are slick and award-decorated, but the filings do not connect the glossy messaging to concrete evidence of margin expansion or customer retention improvements. The 10-Q admits direct expenses rose on third-party software and contractor costs, which is corporate code for “we outsourced the hard yards,” and the board’s late-June equity tweaks read like an attempt to keep incentives aligned without admitting the cash runway is short. Until the next earnings release or an 8-K that names a customer contract or a product milestone, the file remains a study in how marketing and finance can inhabit parallel universes. (source: SEC EDGAR filings and product pages, https://www.sec.gov/Archives/edgar/data/70487/)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
NRC technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on NRC
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep NRC research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
NRC FAQ
What is Nrc Health (NRC)?Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks...
Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for NRC?Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...
Nrc Health (NRC) has a latest verified close of 20.34, up 4.47%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files NRC under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the NRC page updated?The NRC public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The NRC public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for NRC?The NRC file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NRC. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The NRC file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NRC. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on NRC?Yes. The workstation can open NRC, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open NRC, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this NRC page investment advice?No. The NRC page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The NRC page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →
NRC
Equity · evidence first